価格表

在庫・価格 : 2026年04月06日 18時40分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-ERCC1, Mouse-Mono(8F1)
データシート
NB500-704 NOVノバス バイオロジカルス
Novus biologicals, LLC
0.1 ml ¥96,000
(未発注)
追加

在庫・価格 : 2026年04月06日 18時40分 現在

Anti-ERCC1, Mouse-Mono(8F1)

  • 商品コード:NB500-704
  • メーカー:NOV
  • 包装:0.1ml
  • 価格: ¥96,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Soltermann A et al. Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10. J Clin Bioinforma 2011;1:25
Soltermann A et al
2011/01/01
PubMed
2 Ozcan MF et al. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy. Urol. Oncol. 2012 Aug;
Ozcan MF et al
2012/01/01
Species: Human, Applications: IHC PubMed
3 Sodja E et al. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. Eur J Cancer 2012 Jul;
Sodja E et al
2012/01/01
Species: Human, Applications: IHC PubMed
4 Su CH et al. Gemcitabine causes telomere attrition by stabilizing TRF2. Eur J Cancer 2012 Jun;
Su CH et al
2012/01/01
Species: Human, Applications: WB PubMed
5 Lee S et al. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamou
Lee S et al
2010/01/01
PubMed
6 Bepler G et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 2013 Jul;31(19):2404-12
Bepler G et al
2013/01/01
PubMed
7 Al-Minawi AZ et al. The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells. Nucleic Acids Res. 2008 Jan;36(1):1-9
Al-Minawi AZ et al
2008/01/01
PubMed
8 Hwang IG et al. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 2008 Sep;113(6):1379-86
Hwang IG et al
2008/01/01
PubMed
9 Azim HA et al. ERCC1 Expression in Diffuse Large B-Cell Lymphoma Patients Treated with a Cisplatin-Based Regimen : A Brief Communication. J Egypt Natl Canc Inst 2007 Sep;19(3):176-7
Azim HA et al
2007/01/01
PubMed
10 Besse B et al. ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Ann. Oncol. 2011 Mar;22(3):575-81
Besse B et al
2011/01/01
PubMed
11 Jun HJ et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br. J. Cancer 2008 Jul;99(1):167-72
Jun HJ et al
2008/01/01
PubMed
12 Shao YY et al. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. Jpn. J. Clin. Oncol. 2010 Apr;40(4):286-93
Shao YY et al
2010/01/01
PubMed
13 Kim MK et al. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin. Cancer Res. 2008 Jul;14(13):4225-31
Kim MK et al
2008/01/01
PubMed
14 Bhagwat NR et al. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res. 2009 Sep;69(17):6831-8
Bhagwat NR et al
2009/01/01
PubMed
15 Bepler G et al. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 2014 Aug;120(15):2343-51
Bepler G et al
2014/01/01
Species: Human, Applications: IHC-P PubMed
  • No.: 1
  • 文献情報:
    Soltermann A et al. Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10. J Clin Bioinforma 2011;1:25
    Soltermann A et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Ozcan MF et al. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy. Urol. Oncol. 2012 Aug;
    Ozcan MF et al
    2012/01/01
  • 備考:
    Species: Human, Applications: IHC
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Sodja E et al. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. Eur J Cancer 2012 Jul;
    Sodja E et al
    2012/01/01
  • 備考:
    Species: Human, Applications: IHC
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Su CH et al. Gemcitabine causes telomere attrition by stabilizing TRF2. Eur J Cancer 2012 Jun;
    Su CH et al
    2012/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Lee S et al. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamou
    Lee S et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Bepler G et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 2013 Jul;31(19):2404-12
    Bepler G et al
    2013/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Al-Minawi AZ et al. The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells. Nucleic Acids Res. 2008 Jan;36(1):1-9
    Al-Minawi AZ et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Hwang IG et al. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 2008 Sep;113(6):1379-86
    Hwang IG et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Azim HA et al. ERCC1 Expression in Diffuse Large B-Cell Lymphoma Patients Treated with a Cisplatin-Based Regimen : A Brief Communication. J Egypt Natl Canc Inst 2007 Sep;19(3):176-7
    Azim HA et al
    2007/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Besse B et al. ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Ann. Oncol. 2011 Mar;22(3):575-81
    Besse B et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Jun HJ et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br. J. Cancer 2008 Jul;99(1):167-72
    Jun HJ et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Shao YY et al. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. Jpn. J. Clin. Oncol. 2010 Apr;40(4):286-93
    Shao YY et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Kim MK et al. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin. Cancer Res. 2008 Jul;14(13):4225-31
    Kim MK et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Bhagwat NR et al. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res. 2009 Sep;69(17):6831-8
    Bhagwat NR et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Bepler G et al. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 2014 Aug;120(15):2343-51
    Bepler G et al
    2014/01/01
  • 備考:
    Species: Human, Applications: IHC-P
  • 参照:
    PubMed